AbCellera Presents Data on T Cell Engager Platform at AACR 2022
AbCellera (Nasdaq: ABCL) unveiled data on its innovative T cell engager platform at the AACR 2022 Annual Meeting. The research showcases a diverse range of CD3-binding antibodies for developing bispecific T cell engagers aimed at enhancing cancer therapies. Bo Barnhart, VP of Translational Research, emphasized the potential of these new antibodies to boost the efficacy of oncology treatments. The platform combines rapid screening capabilities with favorable developability properties, reducing engineering risks and enhancing the probability of successful cancer drug development.
- Launch of a new T cell engager platform showcasing a diverse panel of CD3-binding antibodies.
- Demonstrated potential for enhancing efficacy in cancer therapies through bispecific T cell engagers.
- Favorable developability properties of CD3-binding antibodies may reduce technical engineering risks.
- None.
“T cell engagers are widely recognized for their tremendous potential as precision oncology therapeutics. However, a limited pool of available CD3-binding antibodies and technological challenges in engineering bispecifics have hindered development, leading to many first-generation molecules with poor efficacy or safety,” said
CD3 T cell engagers, which bind to T cells and cancer cells simultaneously, are able to redirect T cells to tumor cells, regardless of T cell specificity. Two different parental antibodies, a CD3-targeting antibody that fine-tunes T cell activation and a tumor-targeting antibody with high specificity for cancer cells, are needed to create an optimal bispecific T cell engager. Highly diverse panels of developable and functionally validated parental antibodies increase the probability of finding effective and manufacturable CD3 T cell engagers and reduce the need for downstream engineering to eliminate liabilities.
AbCellera used its technology stack to discover a panel of CD3-binding antibodies from humanized mice. Bioinformatic analysis revealed high sequence diversity, including somatic hypermutation, a range of CDR3 lengths, and diverse V gene usage. The panel was also found to be functionally diverse, including a broad range of CD3 affinities and T cell activation potencies. Biophysical characterization demonstrated that AbCellera’s CD3-binding antibodies have favorable developability properties, which may reduce the time and technical risks of downstream protein engineering, including low mean hydrophobicity, self-association, and polyspecificity.
AbCellera used its clinically validated bispecifics platform, OrthoMabTM, to pair the CD3-binding antibodies with a single EGFR-binding arm to validate the panel in bispecific formats. The resulting bispecific antibodies activated T cells with a range of potencies and led to T cell-mediated tumor cell killing of EGFR-expressing cell lines.
“The data from our T cell engager program, which we initiated in late 2021, show the power and speed of AbCellera’s robust platform,” said
Details on AbCellera’s presentation at AACR are as follows:
Title: Redirecting T cells to tumor targets with functionally diverse CD3-binding antibodies
Presenter:
Session: Antibodies and Immune Therapies — Abstract #312
Date and time:
The poster is available for viewing here.
About
AbCellera is a technology company that searches, decodes, and analyzes natural immune systems to find antibodies that its partners can develop into drugs to prevent and treat disease. AbCellera partners with drug developers of all sizes, from large pharmaceutical to small biotechnology companies, empowering them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.
AbCellera Forward-looking Statements
This press release contains forward-looking statements, including statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to management. All statements contained in this release other than statements of historical fact are forward-looking statements, including statements regarding our ability to develop, commercialize and achieve market acceptance of our current and planned products and services, our research and development efforts, and other matters regarding our business strategies, use of capital, results of operations and financial position, and plans and objectives for future operations.
In some cases, you can identify forward-looking statements by the words “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. These risks, uncertainties and other factors are described under "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations" and elsewhere in the documents we file with the
Source:
View source version on businesswire.com: https://www.businesswire.com/news/home/20220408005017/en/
Media:
Business Development:
Investor Relations:
Source:
FAQ
What did AbCellera announce at the AACR 2022 Annual Meeting?
What is the significance of CD3-binding antibodies in cancer treatment?
How does AbCellera's technology facilitate cancer drug development?
When and where was AbCellera's presentation at AACR 2022?
What are the potential risks associated with AbCellera's T cell engager program?
